Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis

Open access
Rochwerg, Bram, Neupane, Binod, Zhang, Yuan, Garcia, Carlos Cuello, Raghu, Ganesh, Richeldi, Luca, Brozek, Jan, Beyene, Joseph, Schünemann, Holger · 2016 · BMC Medicine

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with high morbidity and mortality. Effective treatments for IPF are limited. Several recent studies have investigated novel therapeutic agents for IPF, but very few have addressed their comparative benefits and harms. METHODS: We performed a Bayesian network meta-analysis (NMA) to assess the effects of different treatments for IPF on mortality and serious adverse events (SAEs). We searched MEDLINE and EMBASE for randomized controlled trials (RCTs) up to August 2015. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach served to assess the certainty in the evidence of direct and indirect estimates. We calculated the surface under the cumulative ranking curve (SUCRA) for each treatment. We included parallel group RCTs, including factorial designs, but excluded quasi-randomized and cross-over trials. Studies were only included if they involved adult (≥18 years of age) patients with IPF as defined by the 2011 criteria and examined one of the 10 interventions of interest (ambrisentan, bosentan, imatinib, macitentan, N-acetylcysteine, nintedanib, pirfenidone, sildenafil, prednisone/azathioprine/N-acetylcysteine triple therapy, and vitamin K antagonist). RESULTS: A total of 19 RCTs (5,694 patients) comparing 10 different interventions with placebo and an average follow-up period of 1 year fulfilled the inclusion criteria. SUCRA analysis suggests nintedanib, pirfenidone, and sildenafil are the three treatments with the highest probability of reducing mortality in IPF. Indirect comparison showed no significant difference in mortality between pirfenidone and nintedanib (NMA OR, 1.05; 95% CrI, 0.45-2.78, moderate certainty of evidence), pirenidone and sildenafil (NMA OR, 2.26; 95% CrI, 0.44-13.17, low certainty of evidence), or nintedanib and sildenafil (NMA OR 2.40; 95% CrI, 0.47-14.66, low certainty of evidence). Sildenafil, pirfenidone, and nintedanib were ranked second, fourth, and sixth out of 10 for SAEs. CONCLUSION: In the absence of direct comparisons between treatment interventions, this NMA suggests that treatment with nintedanib, pirfenidone, and sildenafil extends survival in patients with IPF. The SAEs of these agents are similar to the other interventions and include mostly dermatologic and gastrointestinal manifestations. Head-to-head comparisons need to confirm these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-016-0558-x

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of search results
Fig. 1 Flow chart of search resultsCC BY · PubMed Central
Fig. 2 Scatterplot including surface under cumulative ranking curve (SUCRA) value for mortality on the y-axis and SUCRA value for severe adverse events (SAEs) on the x-axis. A higher SUCRA ranking for mortality indicates better survival whereas a higher SUCRA ranking for SAEs indicates fewer events associated with treatment. Cluster analysis demonstrates the division of treatments into two distinct groupings
Fig. 2 Scatterplot including surface under cumulative ranking curve (SUCRA) value for mortality on the y-axis and SUCRA value for severe adverse events (SAEs) on the x-axis. A higher SUCRA ranking for mortality indicates better survival whereas a higher SUCRA ranking for SAEs indicates fewer events associated with treatment. Cluster analysis demonstrates the division of treatments into two distinct groupingsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 102

Metadata

Authors
Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H.
Affiliations
  • McMaster University (CA)
  • University of Washington (US)
  • National Institute for Health and Care Research (GB)
Corresponding author
Rochwerg, Bram
Venue
BMC Medicine
Published
2016-02-03
Volume
14
Issue
1
Pages
18-18
ISSN
1741-7015 (ISSN-L)
OpenAlex
W2267642110
Cited by
101
References
40
Citations by year
2026: 2 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 14 · 2020: 20 · 2019: 6 · 2018: 11 · 2017: 19 · 2016: 3
FWCI
11.63
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, interstitial lung disease, mortality, serious adverse events, nintedanib, pirfenidone, sildenafil, imatinib, macitentan, bosentan, ambrisentan, N-acetylcysteine, vitamin K antagonists, antifibrotic therapy, treatment comparison, indirect comparison, prednisone
MeSH terms
Acetylcysteine, Adult, Anticoagulants, Bayes Theorem, Female, Humans, Immunosuppressive Agents, Indoles, Male, Middle Aged, Pyridones, Quality of Life, Free Radical Scavengers, Treatment Outcome, Idiopathic Pulmonary Fibrosis, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. https://app.cochat.ai/papers/10.1186/s12916-016-0558-x
The paper
Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016). Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Medicine. https://doi.org/10.1186/s12916-016-0558-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.